In turn, TRAIL modification on the viral surface further promoted cell apoptosis (A4 vs. A3), with the dual-modified adenovirus-mediated TRAIL gene therapy being able to efficiently induce glioma cells apoptosis (A4/K37 vs. other groups). This evidence concerns the gene TNFSF10 and central nervous system cancer.